Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 7/20 | 0.35 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.34 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.34 |
| ▸ | IARS2 | Q9NSE4 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | TYMP | P19971 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9352754 | 0.99 | LMNA (0.58) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL10624509 | 0.97 | LMNA (0.57) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL3067086 | 0.96 | LMNA (0.56) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL9188727 | 0.96 | LMNA (0.56) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL8375526 | 0.96 | LMNA (0.56) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL23817080 | 0.96 | LMNA (0.56) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL7995861 | 0.95 | LMNA (0.55) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL9009193 | 0.95 | LMNA (0.55) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL13180643 | 0.93 | LMNA (0.54) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL9581262 | 0.93 | LMNA (0.57) | LMNACYP2C19HIF1AEGFRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114478298-B | Method for purifying contrast agent ioversol | 成都西岭源药业有限公司 | 2024-09-27 | — | — | CN | claimed |
| CN-117756660-A | Method for removing ioversol impurity | 重庆圣华曦药业股份有限公司 | 2024-03-26 | — | — | CN | claimed |
| CN-113166040-B | Method for preparing contrast agent iomeprol | UK化学药剂有限公司 | 2023-10-24 | — | — | CN | claimed |
| EP-3854780-B1 | METHOD FOR PREPARING CONTRAST AGENT IOMEPROL | UK CHEMIPHARM CO LTD (KR) | 2023-10-18 | — | — | EP | claimed |
| CN-116421744-A | Absorbable medical hydrogel and preparation method thereof | 杭州融华再生医学科技有限公司 | 2023-07-14 | — | — | CN | claimed |
| US-11396490-B2 | Method for preparing contrast agent iomeprol | UK CHEMIPHARM CO., LTD (KR) | 2022-07-26 | — | — | US | claimed |
| US-20220024857-A1 | METHOD FOR PREPARING CONTRAST AGENT IOMEPROL | UK CHEMIPHARM CO., LTD (KR) | 2022-01-27 | — | — | US | claimed |
| EP-3854780-A1 | METHOD FOR PREPARING CONTRAST AGENT IOMEPROL | UK Chemipharm Co., Ltd. (KR) | 2021-07-28 | — | — | EP | claimed |
| WO-2008104853-A1 | PROCESSES FOR THE PREPARATION OF PURE IOVERSOL | WOCKHARDT RESEARCH CENTRE (IN) | 2008-09-04 | — | — | WO | claimed |
| US-6596904-B1 | Process for producing ioversol | MALLINC KRODT INC | 2003-07-22 | — | — | US | claimed |
| EP-0839056-B1 | PROCESS FOR PRODUCING IOVERSOL | MALLINCKRODT INC (US) | 2003-05-07 | — | — | EP | claimed |
| EP-0886634-B1 | PROCESS FOR PRODUCING IOVERSOL | MALLINCKRODT INC (US) | 2002-04-24 | — | — | EP | claimed |
| US-5648536-A | Process for producing ioversol | LAFAYETTE PHARMACEUTICALS LLC | 1997-07-15 | — | — | US | claimed |
| EP-0646021-B1 | PURIFICATION OF CRUDE IOVERSOL USING CONTINUOUS DEIONIZATION | MALLINCKRODT MEDICAL INC (US) | 1996-11-27 | — | — | EP | claimed |
| US-5489708-A | PREFERENTIAL HYDROLYSIS OF THE O-ALKYL ISOMER OF 5-(N(2-ACETOXYETHYL)ACETOXYACETAMIDO)-N,N'-BIS(2,3-DIACETOXYPROPYL)-2,4,6 -TRIIODOISOPHTHALAMIDE PRIOR TO ACID HYDROLYSIS OF MIXTURE; BY-PRODUCT INHIBITION, SIMPLIFICATION | MALLINCKRODT MEDICAL, INC. (US) | 1996-02-06 | — | — | US | claimed |
| EP-0646021-A1 | PURIFICATION OF CRUDE IOVERSOL USING CONTINUOUS DEIONIZATION. | MALLINCKRODT MEDICAL INC (US) | 1995-04-05 | — | — | EP | claimed |
| EP-0646021-A4 | PURIFICATION OF CRUDE IOVERSOL USING CONTINUOUS DEIONIZATION. | MALLINCKRODT MEDICAL INC (US) | 1994-10-07 | — | — | EP | claimed |
| WO-1993005820-A1 | PURIFICATION OF CRUDE IOVERSOL USING CONTINUOUS DEIONIZATION | MALLINCKRODT MEDICAL, INC. (US) | 1993-04-01 | — | — | WO | claimed |
| EP-0083964-B1 | COMPOUNDS SUITABLE FOR X-RAY VISUALISATION METHODS | Mallinckrodt, Inc. (a Delaware corporation) (US) | 1986-04-16 | — | — | EP | claimed |
| EP-0083964-A1 | Compounds suitable for X-ray visualisation methods | Mallinckrodt, Inc. (a Delaware corporation) (US) | 1983-07-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024857-A1 | METHOD FOR PREPARING CONTRAST AGENT IOMEPROL | PPIP5K2, SLC5A11, INMT | LMNA 2169/4885CYP2C19 2086/4885HIF1A 676/4885 |
| US-11396490-B2 | Method for preparing contrast agent iomeprol | PPIP5K2, SLC5A11, INMT | LMNA 2169/4885CYP2C19 2086/4885HIF1A 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.